Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bluebird Bio Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://www.bluebirdbio.com
Year Founded: 1992
Status: Public
Industry Sector: HealthTechnology
CEO: Andrew Obenshain, MBA
Number Of Employees: 375
Enterprise Value: $250,927,500
PE Ratio: -0.11
Exchange/Ticker 1: NASDAQ:BLUE
Exchange/Ticker 2: N/A
Latest Market Cap: $36,918,000
BioCentury | Feb 27, 2025
Product Development
Crispr Therapeutics: Controlled risk for accelerated development
An ex vivo gene knockout approach helped the company become first to market with a gene editing therapy
BioCentury | Feb 25, 2025
Product Development
Indication selection: Lessons learned from the CRISPR-Cas9 story
Founding CEOs of gene editing companies discuss their pipeline strategies and lessons learned
BioCentury | Feb 25, 2025
Deals
Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report
Plus Radiance gets ROR1 ADC from Cspc, Astrazeneca buys Fibrogen’s China subsidiary and more
BioCentury | Feb 21, 2025
Deals
With debt looming, Bluebird accepts buyout offer from Carlyle, SK Capital
Incoming CEO Meek would need to drive steep growth in product sales to fulfill highly backloaded deal, with 70% of its value tied up in a CVR
BioCentury | Dec 10, 2024
Management Tracks
Toshinori Agatsuma, Daiichi’s head of research, passes away
Plus: Lange becomes CBO of Avidity and updates from CABS, BIO, Zevra and Achieve
BioCentury | Dec 10, 2024
Product Development
Gene and base editors deliver on fetal hemoglobin expression: ASH24
Editas, Beam report updates on sickle cell genetic therapies at this year’s ASH meeting
BioCentury | Dec 5, 2024
Management Tracks
Várhelyi to lead health at EU
Plus updates from Nouscom, Eton, Healx, Medipost, Fairjourney, Italfarmaco and Cellino
BioCentury | Nov 20, 2024
Product Development
Biotechs now match pharma for FDA approvals
Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
BioCentury | Oct 28, 2024
Product Development
In vivo editing data advances lift hopes for better access
Editas and Tessera report preclinical data for in vivo stem cell editors; Interius doses first patient with an in vivo CAR T
BioCentury | Oct 19, 2024
Finance
Biotech restructurings show signs of slowing
Temporary respite or reflection of a stabilizing sector?
Items per page:
1 - 10 of 484